



National antimicrobial resistance surveillance systems and participation in the Global Antimicrobial Resistance Surveillance System (GLASS)

**A guide to planning, implementation, and
monitoring and evaluation**



**National antimicrobial resistance surveillance systems
and participation in the Global Antimicrobial Resistance
Surveillance System (GLASS)**

**A guide to planning, implementation, and
monitoring and evaluation**



© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Acknowledgments

WHO would like to express its sincere appreciation and gratitude to all those who have supported and contributed to the development of this document.

GLASS Collaborative Platform (2015-16)

Aga Khan University, Karachi, Pakistan (Rumina HASAN), Brigham and Women's Hospital, Boston, USA (John STELLING), Caribbean Public Health Agency, Trinidad and Tobago (Avery HINDS), Centers for Disease Control and Prevention, Atlanta, USA (Scott FRIDKIN, Benjamin PARK, Jean PATEL, Rachel SMITH), European Centre for Disease Prevention and Control, Stockholm, Sweden (Diamantis PLACHOURAS, Liselotte DIAZ HÖGBERG), Institut Pasteur, Paris, France (Arnaud FONTANET), Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Russia (Roman S. KOZLOV), Mahidol University, Thailand (Visanu THAMLIKITKUL), Médecins Sans Frontières, France (Jean-Baptiste RONAT), National Food Institute, Technical University of Denmark (Rene S. HENDRIKSEN), National Institute for Communicable Diseases, South Africa (Olga PEROVIC), National Institute for Public Health and the Environment, Netherlands (Tjalling LEENSTRA, Jos MONEN), National Institute of Health, Thailand (Wantana PAVEENKITTIPORN), National Institute of Public Health, Mexico (Hugo LOPEZ-GATELL), Peking University First Hospital, China (Bo ZHENG), Public Health Agency of Sweden (Olov ASPEVALL, Sonja LÖFMARK, Johan STRUWE), Public Health England (Nandini SHETTY, Neil WOODFORD), The Prince of Wales Hospital, Australia (Monica LAHRA), The University of Hong Kong (Wing Hong SETO), US Naval Medical Research Unit, Cairo, Egypt (Maha TALAAT), WHO African Region (Abayneh DESTA), WHO Eastern Mediterranean Region (Humayun ASGHAR, Ali R MAFI), WHO European Region (Ana Paula COUTINHO REHSE, Danilo LO FO WONG, Saskia NAHRGANG, Hanne Bak PEDERSEN, Susanne PEDERSEN, Jane ROBERTSON, Nienke van de SANDE-BRUINSMA), WHO headquarters (Muna ABU SIN, Awa AIDARA-KANE, Benedetta ALLEGRANZI, Tejinder CHOWDHARY, Sergey EREMIN, Jolanta GRISKEVICIENE, Jung-Kyu LEE, Jorge Raul MATHEU ALVAREZ, Francis MOUSSY, Arno MULLER, Christopher OXENFORD, Carmem Lucia PESSOA-SILVA, Marcus SPRENGER, Elizabeth TAYLER, Peter ULLERYD, Teodora Elvira WI, Matteo ZIGNOL), WHO Region of the Americas (Pilar RAMON PARDO), WHO South-East Asia Region (Aparna Singh SHAH, Sirenda VONG), WHO Western Pacific Region (Klara TISOCKI, Takuya YAMAGISHI).

Developer Group

Muna ABU SIN, Scott FRIDKIN, Sonja LÖFMARK, Carmem Lucia PESSOA-SILVA, Nienke van de SANDE-BRUINSMA.

Executive Group

Muna ABU SIN, Sergey EREMIN, Carmem Lucia PESSOA-SILVA.

Editing

Penelope ANDREA, Breeda HICKEY.

Financial Support

The Governments of Germany, Japan, the Netherlands, the Republic of Korea, Sweden, the United Kingdom and United States of America.

Acronyms

AMR	antimicrobial resistance
AST	antimicrobial susceptibility testing
CLSI	Clinical and Laboratory Standards Institute
EQA	external quality assurance
EUCAST	European Committee on Antimicrobial Susceptibility Testing
GLASS	Global Antimicrobial Resistance Surveillance System
IQC	internal quality control
M&E	monitoring and evaluation
NCC	national coordinating centre
NFP	national focal point
NRL	national reference laboratory
MIC	minimum inhibitory concentration
SOPs	standard operating procedures
WHO	World Health Organization

Contents

1.	Setting up a national AMR surveillance system	1
1.1	Introduction	1
1.2	Conducting a situation analysis	2
1.3	The core components of a national AMR surveillance system	3
2.	Steps in setting up a national AMR surveillance system	7
	Step 1: Establish a National Coordinating Centre.....	7
	Step 2: Define the surveillance objectives	8
	Step 3: Define a strategy for gradual implementation.....	8
	Step 4: Establish a national reference laboratory	11
	Step 5: Develop or adapt national protocols	11
	Step 6: Identify AMR surveillance sites.....	12
	Step 7: Disseminate protocols and tools and train staff in their use	15
	Step 8: Start collecting data on progress or status of implementation and on AMR	16
	Step 9: Report information on the AMR situation.....	16
	Step 10: Monitoring and evaluation.....	17
	Annex 1. Sample indicators for M&E of national AMR surveillance systems participating in GLASS to be used at national level.....	20

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27159

